Pirfenidone-induced hyponatraemia

Insight in mechanism, risk factor and management

Leann Silhan, Panagis Galiatsatos, Justine Corwine, Sonye Danoff

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pirfenidone was approved in October 2014 in the USA for the treatment of idiopathic pulmonary fibrosis. Although not included in the adverse events published in the CAPACITY-1 and CAPACITY-2 or ASCEND trials, hyponatraemia was reported in supplementary data with rate of 3.4% in the active therapy arm versus 0.3% in the placebo arm. We performed a retrospective analysis of patients who were initiated on pirfenidone or nintedanib for the treatment of pulmonary fibrosis at our centre. Of the 52 patients who were started on pirfenidone, three (5.8%) developed severe hyponatraemia. Of the 29 patients who were started on nintedanib, none developed hyponatraemia. Laboratory data suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by pirfenidone and the medication was discontinued. Hyponatraemia is a possible significant adverse effect of pirfenidone, able to induce SIADH in patients taking the medication.

Original languageEnglish (US)
Article number222734
JournalBMJ Case Reports
Volume2017
DOIs
StatePublished - Jan 1 2017

Fingerprint

Hyponatremia
Risk Management
Inappropriate ADH Syndrome
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Therapeutics
Placebos
pirfenidone
nintedanib

Keywords

  • interstitial lung disease
  • unwanted effects / adverse reactions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pirfenidone-induced hyponatraemia : Insight in mechanism, risk factor and management. / Silhan, Leann; Galiatsatos, Panagis; Corwine, Justine; Danoff, Sonye.

In: BMJ Case Reports, Vol. 2017, 222734, 01.01.2017.

Research output: Contribution to journalArticle

Silhan, Leann ; Galiatsatos, Panagis ; Corwine, Justine ; Danoff, Sonye. / Pirfenidone-induced hyponatraemia : Insight in mechanism, risk factor and management. In: BMJ Case Reports. 2017 ; Vol. 2017.
@article{862d5e7bf2f54061813838d17e8816aa,
title = "Pirfenidone-induced hyponatraemia: Insight in mechanism, risk factor and management",
abstract = "Pirfenidone was approved in October 2014 in the USA for the treatment of idiopathic pulmonary fibrosis. Although not included in the adverse events published in the CAPACITY-1 and CAPACITY-2 or ASCEND trials, hyponatraemia was reported in supplementary data with rate of 3.4{\%} in the active therapy arm versus 0.3{\%} in the placebo arm. We performed a retrospective analysis of patients who were initiated on pirfenidone or nintedanib for the treatment of pulmonary fibrosis at our centre. Of the 52 patients who were started on pirfenidone, three (5.8{\%}) developed severe hyponatraemia. Of the 29 patients who were started on nintedanib, none developed hyponatraemia. Laboratory data suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by pirfenidone and the medication was discontinued. Hyponatraemia is a possible significant adverse effect of pirfenidone, able to induce SIADH in patients taking the medication.",
keywords = "interstitial lung disease, unwanted effects / adverse reactions",
author = "Leann Silhan and Panagis Galiatsatos and Justine Corwine and Sonye Danoff",
year = "2017",
month = "1",
day = "1",
doi = "10.1136/bcr-2017-222734",
language = "English (US)",
volume = "2017",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Pirfenidone-induced hyponatraemia

T2 - Insight in mechanism, risk factor and management

AU - Silhan, Leann

AU - Galiatsatos, Panagis

AU - Corwine, Justine

AU - Danoff, Sonye

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pirfenidone was approved in October 2014 in the USA for the treatment of idiopathic pulmonary fibrosis. Although not included in the adverse events published in the CAPACITY-1 and CAPACITY-2 or ASCEND trials, hyponatraemia was reported in supplementary data with rate of 3.4% in the active therapy arm versus 0.3% in the placebo arm. We performed a retrospective analysis of patients who were initiated on pirfenidone or nintedanib for the treatment of pulmonary fibrosis at our centre. Of the 52 patients who were started on pirfenidone, three (5.8%) developed severe hyponatraemia. Of the 29 patients who were started on nintedanib, none developed hyponatraemia. Laboratory data suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by pirfenidone and the medication was discontinued. Hyponatraemia is a possible significant adverse effect of pirfenidone, able to induce SIADH in patients taking the medication.

AB - Pirfenidone was approved in October 2014 in the USA for the treatment of idiopathic pulmonary fibrosis. Although not included in the adverse events published in the CAPACITY-1 and CAPACITY-2 or ASCEND trials, hyponatraemia was reported in supplementary data with rate of 3.4% in the active therapy arm versus 0.3% in the placebo arm. We performed a retrospective analysis of patients who were initiated on pirfenidone or nintedanib for the treatment of pulmonary fibrosis at our centre. Of the 52 patients who were started on pirfenidone, three (5.8%) developed severe hyponatraemia. Of the 29 patients who were started on nintedanib, none developed hyponatraemia. Laboratory data suggested syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by pirfenidone and the medication was discontinued. Hyponatraemia is a possible significant adverse effect of pirfenidone, able to induce SIADH in patients taking the medication.

KW - interstitial lung disease

KW - unwanted effects / adverse reactions

UR - http://www.scopus.com/inward/record.url?scp=85036539134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036539134&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-222734

DO - 10.1136/bcr-2017-222734

M3 - Article

VL - 2017

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - 222734

ER -